Olverembatinib

Chemical structure of Olverembatinib

Olverembatinib is a tyrosine kinase inhibitor (TKI) used in the treatment of certain types of cancer, particularly chronic myeloid leukemia (CML). It is designed to target the BCR-ABL1 fusion protein, which is a constitutively active tyrosine kinase that drives the proliferation of leukemic cells in CML.

Mechanism of Action

Olverembatinib functions by inhibiting the activity of the BCR-ABL1 kinase. This inhibition prevents the phosphorylation of downstream substrates that are essential for the proliferation and survival of leukemic cells. By blocking this pathway, Olverembatinib induces apoptosis in cancer cells and reduces the progression of the disease.

Clinical Use

Olverembatinib is primarily indicated for patients with chronic myeloid leukemia who have developed resistance or intolerance to previous TKI therapies. It is particularly effective against CML with the T315I mutation, which is known to confer resistance to many first- and second-generation TKIs.

Side Effects

Common side effects of Olverembatinib include:

• Myelosuppression
• Gastrointestinal disturbances
• Fatigue
• Headache

Patients are monitored for these side effects, and dose adjustments may be necessary to manage them.

Pharmacokinetics

Olverembatinib is administered orally and has a bioavailability that allows for effective systemic exposure. It is metabolized primarily in the liver and excreted through both renal and fecal pathways.

Development and Approval

Olverembatinib was developed as part of ongoing efforts to overcome resistance mechanisms in CML treatment. It has undergone clinical trials demonstrating its efficacy and safety profile, leading to its approval in several regions for use in resistant CML cases.

Related Pages

• Chronic myeloid leukemia
• Tyrosine kinase inhibitor
• BCR-ABL1
• Cancer treatment